A Broad Range of Release Profiles

Our technologies provide a broad range of release profiles, taking into account the physical and chemical characteristics of a drug product, the therapeutic use of the particular drug, and the optimal site for release of the active pharmaceutical ingredient in the gastrointestinal tract (GIT). We will often use more than one technology to develop a single drug product.

Control Release Delivery Platforms

  • Hypermatrix

    Our Hypermatrix™ technology platform is at the core of a family of drug delivery technologies that underlie our development and marketing programs. Hypermatrix™ is a novel concept based on hyper-dimensionality. The understanding and controlling of properties associated with these dimensions facilitates time-release delivery of a wide range of pharmaceuticals.

    View Hypermatrix Technology 

  • nPODDDS

    The nPODDDS™ technology platform supports our Oxycodone hydrochloride ER new drug candidate, and is designed to provide for certain unique drug delivery features in a product. nPODDDS™ drug release profile shows a clearly defined Point Of Divergence (POD) in the drug release time lines:

    • Initial loading dose provides a quick onset of action
    • Followed by a shift in the drug release rate to reflect a controlled release or sustained action
    View nPODDDS Technology 

  • Other CR Platforms

    Using our Hypermatrix™ concept, we have designed several controlled-release delivery platforms: IntelliFoam™, IntelliGITransporter™, IntelliMatrix™, IntelliOsmotics™, IntelliPaste™, IntelliShuttle™ and IntelliPellets™.

    View Other CR Delivery Platforms 

Abuse Deterrent Technologies

Our Oxycodone hydrochloride ER (abuse deterrent oxycodone hydrochloride extended release tablets) product candidate was developed with properties considered to be abuse deterrent. We have developed a full suite of abuse deterrent physico-chemical properties that are embedded within this new drug candidate.

Learn More

Overdose Prevention Technologies

PODRAS™

The PODRAS™ delivery technology platform was designed to prevent overdose when more pills than prescribed are swallowed intact. Preclinical studies suggest that, unlike other third-party abuse-deterrent oxycodone products in the marketplace, if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected. However, if the prescribed number of pills is swallowed, the drug release should be as expected. We intend to apply PODRAS™ to our Oxycodone hydrochloride ER XR oxycodone drug candidate, although this technology can be applied to any solid dose formulation.

View Prodras Technology